Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System

Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System

Hepatocellular carcinoma (HCC) is a highly malignant tumor related to high mortality and is still lacking a satisfactory cure. Tumor metastasis is currently a major challenge of cancer treatment, which is highly related to angiogenesis. The vascular endothelial growth factor (VEGF)/VEGFR signaling p...

Full description

Bibliographic Details
Main Authors: Xunan Li, Xiang Wang, Nian Liu, Qiuyu Wang, Jing Hu
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Molecules
Subjects:
hepatocellular carcinoma
metastasis
ASGPR
gene therapy
VEGF/VEGFR2 signaling pathway
Online Access:https://www.mdpi.com/1420-3049/27/7/2082

Internet

https://www.mdpi.com/1420-3049/27/7/2082

Similar Items